middl
east
respiratori
syndrom
mer
aris
infect
merscoronaviru
merscov
beta
coronaviru
sinc
first
confirm
case
june
world
health
organ
inform
laboratoryconfirm
case
result
least
death
middl
east
respiratori
syndrom
coronaviru
merscov
zaki
et
al
although
case
arisen
countri
date
includ
major
outbreak
republ
korea
overwhelm
burden
infect
occur
middl
east
particularli
kingdom
saudi
arabia
ksa
case
occur
accord
estim
middl
east
respiratori
syndrom
coronaviru
merscov
middl
east
respiratori
syndrom
coronaviru
merscov
fact
sheet
nishiura
et
al
b
park
et
al
review
consid
current
knowledg
merscov
virolog
molecular
biolog
immunolog
epidemiolog
diagnosi
transmiss
therapi
vaccinolog
special
refer
impact
middl
east
ksa
particular
first
confirm
case
middl
east
respiratori
syndrom
mer
june
previous
healthi
old
saudi
male
hospit
june
bisha
kingdom
saudi
arabia
ksa
acut
communityacquir
pneumonia
subsequ
transfer
privat
hospit
jeddah
june
die
june
due
respiratori
renal
failur
zaki
et
al
indirect
immunofluoresc
assay
day
sputum
sampl
neg
influenza
b
parainfluenza
respiratori
syncyti
viru
adenoviru
howev
cytopath
chang
vero
cell
inocul
patient
sputum
indic
likelihood
viral
replic
zaki
et
al
pcr
test
neg
adenoviru
enteroviru
metapneumoviru
herpesvirus
paramyxovirus
posit
detect
coronavirus
zaki
et
al
sequenc
pcr
product
confirm
identif
new
viru
belong
lineag
c
betacoronaviru
genu
initi
name
human
coronaviru
emc
hcovemc
zaki
et
al
septemb
viru
identifi
man
transfer
hospit
qatar
london
unexplain
sever
respiratori
ill
requir
intub
ventil
bermingham
et
al
importantli
man
histori
travel
ksa
experienc
mild
undiagnos
respiratori
ill
august
bermingham
et
al
first
cluster
human
case
retrospect
confirm
group
peopl
becom
ill
unexplain
respiratori
ill
public
hospit
zarqa
citi
jordan
april
hijawi
et
al
sinc
outbreak
occur
ksa
includ
cluster
case
alhasa
april
may
assiri
et
al
laboratoryconfirm
case
jeddah
januari
may
drosten
et
al
oboho
et
al
case
king
fahad
medic
citi
riyadh
march
may
contemporan
outbreak
riyadh
hospit
march
april
almekhlafi
et
al
fagbo
et
al
case
king
abulaziz
medic
citi
riyadh
late
junel
august
balkhi
et
al
except
major
outbreak
occur
republ
korea
may
juli
nishiura
et
al
b
park
et
al
outbreak
encompass
merscov
case
result
death
middl
east
respiratori
syndrom
coronaviru
merscov
republ
korea
nishiura
et
al
b
howev
common
case
arisen
countri
outsid
middl
east
korean
outbreak
began
man
preced
travel
histori
middl
eastern
countri
accord
report
made
center
diseas
control
prevent
cdc
laboratoryconfirm
case
mer
occur
middl
eastern
countri
includ
ksa
bahrain
iran
jordan
kuwait
lebanon
oman
qatar
unit
arab
emir
uae
yemen
well
countri
outsid
middl
east
includ
algeria
austria
china
egypt
franc
germani
greec
itali
malaysia
netherland
philippin
republ
korea
thailand
tunisia
turkey
unit
kingdom
uk
unit
state
america
usa
associ
individu
travel
histori
middl
east
merscov
includ
list
prioriti
blueprint
diseas
urgent
need
acceler
research
develop
potenti
caus
public
health
emerg
absenc
efficaci
drug
andor
vaccin
list
blueprint
prioriti
diseas
case
continu
aris
ksa
exact
high
mortal
rate
includ
case
area
countri
report
nation
ihr
focal
point
decemb
januari
result
death
middl
east
respiratori
syndrom
coronaviru
merscov
saudi
arabia
frequent
small
outbreak
includ
cluster
case
al
jawf
region
ksa
ie
cluster
case
hospit
august
among
healthcar
worker
hcw
case
dawmet
aljand
citi
august
middl
east
respiratori
syndrom
coronaviru
merscov
saudi
arabia
b
cluster
riyadh
hospit
june
relat
individu
infect
die
coronaviru
infect
clearli
merscov
seriou
public
health
issu
ksa
extend
outbreak
diseas
focus
healthcar
facil
transmiss
appar
depend
close
humantohuman
contact
almekhlafi
et
al
assiri
et
al
balkhi
et
al
drosten
et
al
fagbo
et
al
oboho
et
al
emerg
diseas
therefor
profound
impact
infect
control
prevent
procedur
ksa
outbreak
healthcar
facil
associ
defect
inadequ
infect
prevent
control
measur
balkhi
et
al
butt
et
al
cotten
et
al
hast
et
al
public
health
author
ksa
work
identifi
shortcom
infect
control
procedur
healthcar
facil
contribut
merscov
transmiss
middl
east
respiratori
syndrom
coronaviru
merscov
problem
identifi
includ
emerg
room
overcrowd
neglect
basic
infect
prevent
control
measur
handwash
middl
east
respiratori
syndrom
coronaviru
merscov
ksa
ministri
health
updat
guidelin
infect
prevent
control
line
recommend
butt
et
al
hast
et
al
ministri
health
specifi
standard
precaut
adher
patient
interact
within
hospit
supplement
specif
precaut
suspect
confirm
merscov
case
scientif
advisori
board
ministri
health
kingdom
saudi
arabia
nd
infect
prevent
control
measur
includ
comprehens
basic
procedur
hand
hygien
includ
applic
moment
hand
hygien
save
live
clean
hand
respiratori
precaut
contact
control
use
person
protect
equip
ppe
compris
surgic
correctli
fit
seal
mask
glove
gown
goggl
face
shield
indic
prevent
overcrowd
emerg
room
advanc
precaut
care
patient
acut
respiratori
infect
includ
use
effect
triag
droplet
airborn
precaut
safe
patient
transport
continu
train
educ
healthcar
worker
frequent
thorough
clean
mer
patient
room
special
attent
frequent
touch
surfac
prefer
design
welltrain
housekeep
staff
clearli
defin
scope
clean
patientcar
equip
also
recommend
scientif
advisori
board
ministri
health
kingdom
saudi
arabia
nd
ministri
health
guidelin
also
follow
clean
disinfect
mer
patient
discharg
handl
textil
use
dispos
dish
eat
utensil
merscov
patient
dipos
medic
wast
scientif
advisori
board
ministri
health
kingdom
saudi
arabia
nd
detail
guidelin
includ
manag
contact
merscov
patient
includ
household
contact
healthcar
worker
patient
contact
monitor
day
date
exposur
recommend
scientif
advisori
board
ministri
health
kingdom
saudi
arabia
nd
home
isol
procedur
durat
isol
precaut
base
laboratori
test
avail
assur
absenc
viral
shed
appropri
durat
isol
area
still
research
scientif
advisori
board
ministri
health
kingdom
saudi
arabia
nd
handl
bodi
mortuari
well
guidelin
extracorpor
membran
oxygen
ecmo
avail
design
merscov
center
riyadh
jeddah
dammam
uncertain
benefit
merscov
treatment
also
detail
scientif
advisori
board
ministri
health
kingdom
saudi
arabia
nd
implement
infect
prevent
control
guidelin
merscov
line
uptod
case
definit
surveil
guidanc
result
declin
case
ksa
scientif
advisori
board
ministri
health
kingdom
saudi
arabia
nd
howev
dilig
need
maintain
surveil
standard
further
understand
transmiss
pattern
within
ksa
elsewher
comparison
epidemiolog
ksa
outbreak
republ
korea
outbreak
suggest
similar
term
mean
age
infect
individu
respect
higher
risk
infect
death
older
male
nevertheless
evid
transmiss
pattern
risk
factor
differ
ksa
chen
et
al
korea
transmiss
pattern
almost
exclus
nosocomi
ksa
zoonot
transmiss
humantohuman
transmiss
unknown
pathway
present
addit
nosocomi
infect
chen
et
al
case
ksa
outbreak
exposur
risk
unknown
chen
et
al
thu
addit
infect
prevent
control
guidelin
healthcar
facil
also
issu
guidanc
potenti
zoonot
transmiss
commun
particular
respect
dromedari
camel
recogn
major
merscov
host
reservoir
anim
sourc
human
infect
middl
east
respiratori
syndrom
coronaviru
merscov
fact
sheet
ksa
recommend
peopl
visit
place
dromedari
camel
present
practic
gener
hygien
measur
avoid
contact
sick
anim
furthermor
consumpt
raw
uncook
meat
milk
urin
dromedari
discourag
pasteur
cook
heat
treatment
recommend
render
product
fit
consumpt
middl
east
respiratori
syndrom
coronaviru
merscov
fact
sheet
immunocompromis
peopl
vulner
group
peopl
diabet
renal
failur
chronic
lung
diseas
advis
avoid
contact
dromedari
gener
consum
camel
food
product
pasteur
adequ
cook
middl
east
respiratori
syndrom
coronaviru
merscov
fact
sheet
recent
studi
includ
base
serolog
evid
support
role
dromedari
camel
import
zoonot
sourc
human
merscov
infect
merscov
antibodi
present
dromedari
camel
test
middl
east
mani
african
countri
ali
et
al
chu
et
al
farag
et
al
hemida
et
al
hemida
et
al
hemida
et
al
et
al
reusken
et
al
dromedari
camel
exposur
within
week
ill
onset
identifi
signific
risk
factor
studi
examin
merscov
infect
case
document
may
novemb
ksa
alraddadi
et
al
chang
dromedari
camel
product
farm
practic
includ
intensif
locat
close
citi
may
contribut
zoonot
transmiss
ksa
gossner
et
al
thu
ksa
emerg
merscov
impact
agricultur
anim
husbandri
food
product
veterinari
field
well
infect
prevent
control
procedur
healthcar
set
hemida
et
al
exampl
associ
calv
season
merscov
infect
dromedari
camel
highest
risk
merscov
infect
calv
compar
adult
cow
led
suggest
wean
calv
could
delay
reduc
opportun
human
exposur
calv
hemida
et
al
hemida
et
al
furthermor
need
increas
understand
implic
term
merscov
transmiss
spread
well
viral
exchang
amplif
dissemin
econom
import
bidirect
movement
camel
african
countri
middl
east
includ
ksa
hemida
et
al
meanwhil
case
merscov
suspect
effect
identif
achiev
molecular
method
current
whorecommend
method
use
ksa
base
polymeras
chain
reaction
pcr
target
number
merscov
gene
made
possibl
develop
understand
merscov
classif
genom
first
human
respiratori
illnesscaus
coronavirus
hcov
discov
becker
et
al
hamr
procknow
new
cov
name
sever
acut
respiratori
syndrom
sar
cov
sar
involv
seri
intern
outbreak
caus
close
death
marra
et
al
peiri
et
al
rota
et
al
human
coronavirus
discov
also
caus
human
respiratori
ill
fouchier
et
al
van
der
hoek
et
al
merscov
first
isol
septemb
initi
name
human
coronaviru
emc
zaki
et
al
coronaviru
studi
group
later
renam
novel
viru
middl
east
respiratori
syndrom
coronaviru
merscov
reflect
origin
de
groot
et
al
coronavirus
cov
member
coronavirina
subfamili
coronavirida
famili
cov
infect
human
well
speci
subfamili
compris
genera
alpha
cov
beta
cov
gamma
cov
delta
cov
fig
cov
envelop
singlestrand
positivesens
rna
virus
genom
kilobas
kb
alphacov
sarscov
merscov
beta
coronoavirus
fig
beta
coronavirs
subdivid
lineag
merscov
uniqu
among
cov
infect
human
belong
lineag
c
lineag
beta
cov
fig
corman
et
al
de
groot
et
al
bat
potenti
main
merscov
mammalian
reservoir
coronavirus
drexler
et
al
close
relat
lineag
virus
includ
bat
virus
neocov
isol
neoromicia
zuluensi
bat
south
africa
prototyp
lineag
c
betacoronavirus
tylonycteri
bat
viru
pipistrellu
bat
viru
fig
middl
east
respiratori
syndrom
coronaviru
merscov
fact
sheet
corman
et
al
ithet
et
al
studi
phylogeni
lineag
c
betacoronavirus
suggest
evolut
merscov
camel
occur
prior
human
exchang
genet
element
among
ancestr
virus
either
bat
within
camel
genet
mix
vessel
lead
merscov
emerg
potenti
import
mammalian
host
member
eulipotyphla
taxon
closest
sister
taxon
bat
includ
hedgehog
corman
et
al
ericov
anoth
lineag
c
viru
close
relat
merscov
bat
lineag
c
coronavirus
found
present
approxim
european
hedgehog
erinaceu
europaeu
fecal
sampl
studi
germani
corman
et
al
merscov
genom
nucleotid
compris
predict
open
read
frame
orf
structur
gene
encod
spike
nucleocapsid
n
membran
envelop
e
protein
fig
forni
et
al
mackay
arden
zhang
et
al
overlap
locat
end
singl
strand
posit
rna
alongsid
nucleotid
untransl
region
utr
fig
compris
major
merscov
genom
translat
polyprotein
cleav
viral
proteas
give
nonstructur
protein
term
fig
form
replicationtranscript
complex
rtc
viru
individu
nsp
protein
differ
role
viral
replic
exampl
papainlik
proteas
plpro
activ
mediat
initi
process
forni
et
al
hagemeij
et
al
neuman
et
al
also
work
anchor
viral
rtc
intracellular
membran
form
reticulovesicular
membran
network
viral
rna
replic
meanwhil
also
proteas
activ
proteas
also
mediat
cleavag
nsp
medat
primermak
activ
regul
main
viral
rnadepend
rna
polymeras
rdrp
forni
et
al
hagemeij
et
al
neuman
et
al
involv
viral
rna
modif
forni
et
al
hagemeij
et
al
neuman
et
al
gene
e
n
protein
downstream
fig
protein
vital
merscov
transmiss
host
cell
infect
determin
tropism
viru
host
cell
entri
protein
trimer
envelop
protein
cleav
host
proteas
ntermin
ctermin
subunit
subunit
contain
receptor
bind
domain
rbd
mediat
bind
protein
host
cell
human
dipeptidyl
peptidas
receptor
wang
et
al
merscov
bind
via
rbd
endocytosi
occur
cleavag
junction
occur
mediat
host
proteas
includ
serin
proteas
endosom
cathepsin
l
furin
proteas
millet
whittak
qian
et
al
shirato
et
al
yang
et
al
zhang
et
al
follow
viral
fusion
host
cell
membran
mediat
subunit
subunit
contain
fusion
peptid
heptad
repeat
domain
transmembran
tm
domain
durai
et
al
fusion
facilit
rearrang
bundl
fusion
core
centr
trimer
dimer
fold
allow
exposur
fusion
peptid
insert
host
cell
membran
henc
fusion
durai
et
al
zhang
et
al
merscov
protein
receptor
wide
express
human
cell
includ
lower
respiratori
tract
non
ciliat
bronchial
epithelium
kidney
epitheli
cell
small
intestin
cell
lymphocyt
macrophag
alqahtani
et
al
boonack
van
noorden
tang
et
al
widagdo
et
al
limit
express
upper
respiratori
tract
epithelium
human
compar
dromedari
camel
may
contribut
limit
replic
merscov
human
upper
respiratori
tract
restrict
humantohuman
transmiss
widagdo
et
al
infect
macrophag
lentivir
particl
pseudotyp
merscov
protein
result
attenu
macrophag
respons
via
express
irakm
neg
regul
tolllik
receptor
tlr
signal
transcript
repressor
alqahtani
et
al
use
inhibitor
sitagliptin
reduc
effect
merscov
protein
irakm
indic
suppress
macrophag
immun
respons
merscov
mediat
via
alqahtani
et
al
mathemat
model
suggest
reduc
rate
express
would
reduc
merscov
spread
tang
et
al
inde
level
mrna
protein
higher
lung
tissu
smoker
individu
chronic
obstruct
pulmonari
diseas
copd
compar
neversmok
sey
et
al
smoke
copd
associ
increas
suscept
merscov
infect
host
speci
restrict
merscov
infect
link
residu
key
interact
protein
rbd
peck
et
al
van
doremalen
et
al
phylogenet
analys
shown
residu
either
conserv
differ
one
residu
speci
permiss
either
vitro
vivo
includ
camel
macaqu
marmoset
goat
pig
civet
hors
multipl
variat
nonpermiss
speci
includ
mous
hamster
ferret
peck
et
al
host
cell
mediat
may
also
involv
along
merscov
protein
bind
viral
infect
recent
viru
overlay
protein
bind
assay
vopba
studi
carcinoembryon
antigenrel
cell
adhes
molecul
identifi
anoth
merscov
cell
surfac
bind
target
interact
protein
cell
cultur
overexpress
could
independ
support
merscov
entri
nonpermiss
cell
enhanc
viral
attach
permiss
cell
overexpress
enhanc
viral
entri
conjunct
merscov
also
shown
bind
high
specif
low
affin
sialic
acid
sia
hemagglutin
assay
human
erythrocyt
intact
viru
domain
subdomain
express
nanoparticl
could
bind
siadepend
human
erythrocyt
mucin
sia
deplet
surfac
human
airway
cell
reduc
merscov
viral
entri
thu
addit
express
sia
may
also
contribut
merscov
host
rang
tissu
tropism
human
respiratori
tract
primari
target
infect
merscov
muller
et
al
zielecki
et
al
bronchial
epitheli
cell
bronchiolar
epitheli
cell
alveolar
epitheli
cell
endotheli
cell
pulmonari
vessel
found
infect
viru
ex
vivo
human
lung
tissu
hock
et
al
mackay
arden
muller
et
al
raj
et
al
sey
et
al
tang
et
al
widagdo
et
al
zielecki
et
al
human
intestin
tract
recent
propos
altern
rout
merscov
infect
zhou
et
al
human
primari
intestin
epitheli
cell
small
intestin
explant
intestin
organoid
shown
suscept
merscov
infect
replic
enter
merscov
identifi
clinic
patient
stool
sampl
zhou
et
al
mice
direct
intragastri
inocul
merscov
result
lethal
infect
histolog
demonstr
presenc
enter
infect
inocul
mice
develop
sequenti
respiratori
infect
zhou
et
al
merscov
target
innat
adapt
human
immun
respons
number
direct
indirect
way
featur
merscov
infect
spread
occurr
nosocomi
outbreak
recent
outbreak
occur
may
june
report
merscov
case
simultan
cluster
differ
healthcar
facil
riyadh
case
fatal
amer
et
al
outbreak
highlight
need
develop
rapid
pointofcar
test
enabl
emerg
room
healthcar
staff
rapidli
identifi
merscov
case
outbreak
result
delay
diagnosi
merscov
patient
present
acut
renal
failur
directli
expos
contact
includ
healthcar
worker
patient
hour
spent
open
area
emerg
depart
hemodialysi
session
amer
et
al
hospit
outbreak
fact
merscov
case
saudi
arabia
classifi
due
humantohuman
transmiss
contact
asymptomat
symptomat
individu
difficulti
inher
distinguish
clinic
featur
merscov
infect
respiratori
tract
infect
highlight
import
specif
pointofcar
test
high
degre
clinic
awar
among
clinic
staff
saudi
arabia
detect
positivestrand
rna
virus
merscov
host
innat
immun
system
depend
recognit
pathogenassoci
molecular
pattern
pamp
host
pattern
recognit
receptor
prr
tolllik
receptor
tlr
tenoev
import
pamp
relev
merscov
viral
doublestrand
ds
rna
host
cell
innat
immun
respons
dsrna
involv
induct
type
interferon
ifn
express
via
helicas
includ
well
activ
includ
activ
protein
kinas
r
pkr
reduc
translat
infect
host
cell
activ
synthetas
oa
rnasel
pathway
degrad
viral
rna
schneider
et
al
tenoev
importantli
merscov
significantli
suscept
type
interferon
ifn
mediat
innat
immun
respons
sarscov
also
strategi
evad
respons
common
coronavirus
merscov
plpro
remov
ubiquitin
ub
deubiquitin
dub
interferonstimul
gene
deisgyl
host
cell
protein
turn
block
product
henc
reduc
interferon
respons
cell
line
studi
et
al
daczkowski
et
al
merscov
contain
endonucleas
endou
activ
also
recent
shown
primari
cell
line
macrophag
reduc
earli
innat
immun
respons
inhibit
pkr
oa
respons
ifn
activ
kindler
et
al
viral
omethyltransferas
omtas
also
recent
implic
viral
pathogenesi
type
iifn
inhibit
primari
human
airway
cell
cultur
vivo
mous
model
menacheri
et
al
meanwhil
nonstructur
protein
well
structur
protein
implic
ifn
antagon
inhibit
innat
immun
respons
cell
cultur
studi
canton
et
al
matthew
et
al
menacheri
et
al
rabouw
et
al
siu
et
al
thornbrough
et
al
yang
et
al
yang
et
al
lack
homolog
merscov
sarscov
accessori
gene
highlight
fact
immun
defens
mechan
may
differ
virus
delet
merscov
shown
vitro
vivo
mous
model
impact
viral
replic
pathogenesi
via
dysregul
host
cell
respons
includ
increas
activ
ifn
pathway
induct
inflammatori
respons
menacheri
et
al
shown
partial
modul
inflammationassoci
transcript
factor
menacheri
et
al
protein
shown
cell
cultur
studi
inhibit
ifnand
signal
product
oa
rnasel
pathway
matthew
et
al
thornbrough
et
al
yang
et
al
presenc
merscovinfect
cell
result
tether
cytoplasm
locat
nucleu
canton
et
al
howev
absenc
presenc
mutant
lack
nuclear
local
signal
nl
transloc
nucleu
induc
proinflammatori
cytokin
express
canton
et
al
transloc
inhibit
appear
mediat
bind
protein
essenti
nuclear
transloc
canton
et
al
bind
infect
inhibit
interact
subunit
potenti
particularli
potent
ifninhibit
target
product
signal
via
interferonsensit
respons
element
isr
promot
element
yang
et
al
inhibit
ifn
product
link
vitro
bind
host
cell
dsrnabind
protein
interferoninduc
doublestrand
rnadepend
protein
kinas
activ
pact
critic
innat
immun
mediat
respons
activ
henc
type
respons
coronaviru
infect
siu
et
al
link
inhibit
pkrinduc
stress
respons
pact
pkrassoci
protein
rabouw
et
al
dsrna
bind
protein
henc
effect
mask
viral
dsrna
pamp
host
innat
immun
respons
batool
et
al
includ
alveolar
macrophagesand
induc
proinflammatori
chemotact
cytokin
chemokin
express
infect
macrophag
zhou
et
al
zhou
et
al
bind
infect
merscov
support
express
receptor
alveolar
macrophag
meyerholz
et
al
level
higher
alveolar
macrophag
well
alveolar
epitheli
cell
individu
preexist
pulmonari
diseas
cystic
fibrosi
chronic
obstruct
pulmonari
diseas
could
predispos
merscov
morbid
mortal
meyerholz
et
al
human
monocytederiv
macrophag
mdm
merscov
product
infect
induc
express
antivir
induc
similar
level
interleukin
il
tumor
necrosi
factor
tnf
sarscov
significantli
higher
level
proinflammatori
cytokin
includ
chemokin
includ
zhou
et
al
could
contribut
level
pulmonari
inflamm
tissu
damag
associ
merscov
induc
progress
pneumonia
hand
recent
studi
differenti
macrophag
infect
lentivir
particl
pseudotyp
merscov
protein
suggest
macrophag
respons
includ
product
reduc
lpsinduc
product
immunosuppress
increas
alqahtani
et
al
increas
product
mediat
bind
activ
irakm
neg
regul
tlr
signal
transcript
repressor
alqahtani
et
al
result
suggest
merscov
may
employ
irakm
evad
destruct
macrophag
vitro
studi
antigenpres
cell
apc
shown
human
plasmacytoid
dendrit
cell
pdc
could
infect
merscov
unlik
b
cell
macrophag
monocytederiv
dendrit
cell
mddc
secret
type
iand
type
iiiifn
upon
merscov
infect
accompani
initi
step
viral
infect
replic
evidenc
increas
n
protein
rna
infect
cell
product
replic
viral
amplif
recent
studi
suggest
matur
mddc
seem
permiss
merscov
infect
immatur
mddc
permiss
unlik
macrophag
infect
vitro
result
upregul
proinflammatori
cytokin
chemokin
product
cong
et
al
dendrit
cell
enter
peripher
tissu
carri
antigen
lymphoid
tissu
suggest
may
contribut
merscov
dissemin
act
vehicl
possibl
explain
isol
merscov
specimen
respiratori
tract
sampl
blood
stool
urin
merscov
infect
patient
gueri
et
al
one
cell
cultur
studi
merscov
sarscov
could
effici
infect
human
primari
cell
includ
cell
peripher
blood
spleen
tonsil
cell
appear
suscept
cell
infect
result
receptor
downregul
cell
apoptosi
extrins
intrins
pathway
spleen
tonsil
cell
appar
vulner
higher
degre
infect
apoptosi
peripher
blood
cell
infect
common
marmoset
merscov
result
dissemin
viru
spleen
infect
cell
vivo
result
recent
studi
transgen
mous
model
express
human
suggest
deplet
cell
could
actual
protect
merscovinduc
patholog
symptom
wherea
deplet
macrophag
exacerb
patholog
symptom
coleman
et
al
meanwhil
recent
vitro
studi
suggest
common
influenza
viru
merscov
attempt
evad
adapt
immun
respons
downregul
antigenpresent
gene
express
mediat
epigenet
mechan
menacheri
et
al
downregul
gene
human
airway
epitheli
cell
line
includ
hlaa
b
c
whose
express
increas
presenc
sarscov
infect
well
transcript
factor
ctiia
gene
express
element
antigen
process
machineri
hlaa
b
c
peptid
also
decreas
merscov
infect
although
reduc
hlaa
andc
peptid
case
merscov
major
epigenet
mechan
appear
dna
methyl
wherea
employ
number
mechan
menacheri
et
al
result
use
mutant
virus
suggest
host
viral
process
involv
antigen
present
downregul
although
conclus
await
definit
data
menacheri
et
al
term
humor
respons
merscov
protein
shown
immunogen
merscov
antigen
central
neutral
antibodi
cell
respons
merscov
zhang
et
al
result
protein
target
number
propos
merscov
vaccin
recent
extens
review
rabaan
et
al
consid
detail
light
pathogen
merscov
abil
potenti
evad
immun
system
high
mortal
rate
vital
accur
case
definit
criteria
establish
updat
knowledg
viru
expand
particular
concern
ksa
remain
site
greatest
number
case
cdc
regularli
updat
case
definit
order
help
healthcar
profession
recognit
classif
case
case
definit
categor
patient
either
confirm
probabl
case
cdc
defin
confirm
case
patient
laboratori
confirm
merscov
regardless
clinic
present
center
diseas
control
prevent
world
health
organ
nd
laboratori
confirm
current
defin
via
detect
viral
nucleic
acid
serolog
base
cdc
definit
shown
tabl
viral
nucleic
acid
confirm
either
posit
result
nucleic
acid
amplif
assay
naat
exampl
revers
transcript
polymeras
chain
reaction
rtpcr
direct
minimum
specif
genom
target
either
upstream
e
protein
gene
upe
n
gene
singl
posit
target
sequenc
second
target
prefer
rnadepend
rna
polymeras
rdrp
n
gene
al
johani
hajeer
center
diseas
control
prevent
corman
et
al
corman
et
al
world
health
organ
nd
usa
emerg
use
author
eua
issu
fda
author
use
whoapprov
merscov
rtpcr
kit
current
fdaclearedapprov
test
avail
merscov
test
usa
center
diseas
control
prevent
corman
et
al
food
drug
administr
lu
et
al
serolog
case
confirm
requir
demonstr
seroconvers
sampl
ideal
taken
least
day
apart
screen
test
includ
enzymelink
immunosorb
assay
elisa
immunofluoresc
assay
ifa
neutral
assay
confirm
world
health
organ
nd
cdc
approach
also
adopt
involv
one
screen
test
elisa
confirmatori
test
ifa
microneutr
detect
merscov
antibodi
tabl
center
diseas
control
prevent
cdc
specifi
serolog
test
surveil
investig
purpos
rather
diagnosi
differ
possibl
definit
probabl
case
accord
criteria
involv
febril
patient
respiratori
diseas
either
evid
pulmonari
parenchym
diseas
eg
pneumonia
acut
respiratori
distress
syndrom
ard
sever
along
criteria
shown
tabl
includ
resid
recent
travel
middl
east
direct
epidemiolog
link
laboratoryconfirm
case
world
health
organ
nd
cdc
criteria
probabl
case
person
investig
pui
also
shown
tabl
involv
patient
febril
andor
evid
respiratori
ill
acut
otherwis
along
criteria
includ
recent
travel
healthcar
facil
near
arabian
peninsula
close
contact
laboratoryconfirm
case
center
diseas
control
prevent
sever
assay
detect
merscov
rna
develop
use
realtim
pcr
corman
colleagu
introduc
assay
target
region
upstream
e
protein
upe
fig
corman
et
al
corman
et
al
b
high
sensit
rtpcr
upe
rtpcr
compar
render
valuabl
option
screen
merscov
rna
corman
et
al
corman
et
al
b
world
health
organ
cdc
valid
suggest
altern
test
strategi
base
screen
one
n
gene
signatur
sequenc
combin
upe
test
enhanc
sensit
second
n
gene
signatur
confirm
posit
test
lu
et
al
world
health
organ
corman
colleagu
ultim
develop
upe
realtim
pcr
merscov
rtpcr
kit
clinic
valid
use
sampl
german
merscov
case
respiratori
sampl
respiratori
diseas
patient
corman
et
al
merscov
rtpcr
kit
approv
grant
fda
emerg
use
author
eua
unit
state
food
drug
administr
world
health
organ
nd
studi
group
introduc
rtpcr
assay
sequenc
rdrp
gene
rdrpseq
assay
n
gene
nseq
assay
recommend
confirmatori
test
corman
et
al
although
merscov
rtpcr
kit
upe
kit
approv
ce
permit
fda
emerg
use
author
eua
sever
fever
symptom
respiratori
ill
necessarili
pneumonia
healthcar
facil
patient
worker
visitor
within
day
symptom
onset
countri
territori
near
arabian
peninsula
recent
healthcareassoci
case
mer
identifi
acut
febril
respiratori
ill
sever
direct
epidemiolog
link
confirm
merscov
case
test
merscov
inconclus
fever
symptom
respiratori
ill
necessarili
pneumonia
close
contact
confirm
mer
case
case
ill
merscov
rna
detect
kit
develop
exampl
recent
studi
commerci
avail
realtim
rtpcr
merscov
rna
detect
kit
base
upe
analyz
clinic
valid
nasopharyng
swab
taken
outbreak
korea
kim
et
al
result
suggest
sensit
specif
assay
system
would
suffici
confirm
merscov
infect
although
use
appropri
intern
control
would
import
specimen
pcr
inhibit
issu
kim
et
al
anoth
recent
studi
merscov
rgene
rrtpcr
assay
franc
target
protein
gene
shown
compar
accuraci
recommend
inhous
rrtpcr
assay
target
upe
set
respiratori
sampl
lee
et
al
loopmedi
isotherm
amplif
rt
pcr
assay
rtlamp
also
develop
field
use
given
rapid
result
high
sensit
profil
requir
minim
instrument
thu
also
use
portabl
pointofcar
test
bhadra
et
al
assay
target
small
rna
molecul
leader
sequenc
good
sensit
profil
chan
et
al
respiratori
specimen
nasopharyng
swab
sputum
tracheal
aspir
bronchoalveolar
lavag
bal
commonli
use
detect
viral
rna
result
test
patient
ksa
elsewher
compar
viral
load
genom
fraction
yield
among
respiratori
specimen
obtain
differ
site
shown
lower
respiratori
sampl
eg
tracheal
aspir
bronchoalveolar
lavag
yield
significantli
higher
viral
load
genom
fraction
compar
upper
respiratori
tract
sampl
gueri
et
al
memish
et
al
context
merscov
test
rsa
elsewher
mean
recommend
lower
respiratori
tract
specimen
collect
whenev
possibl
world
health
organ
howev
case
seri
ksa
also
show
valu
collect
test
upper
respiratori
tract
specimen
nasopharyngealoropharyng
swab
long
nasopharyng
swab
taken
nasopharynx
follow
guidelin
nostril
nasopharyng
oropharyng
swab
place
tube
world
health
organ
thu
recommend
possibl
upper
lower
respiratori
tract
specimen
collect
specimen
site
outsid
respiratori
tract
use
routin
diagnost
test
world
health
organ
recommend
sampl
collect
symptomat
patient
naat
test
present
follow
repeat
sequenti
sampl
everi
day
result
neg
sequenti
sampl
confirm
viral
clearanc
world
health
organ
diagnosi
merscov
camel
highli
relev
ksa
context
molecular
test
base
naat
alway
feasibl
option
larg
due
expens
impract
carri
larg
number
test
anim
herd
time
manner
recognit
need
rel
afford
test
use
diagnosi
camel
would
also
sensit
specif
led
develop
immunochromatograph
assay
ica
rapid
direct
qualit
detect
merscov
antigen
test
base
use
monoclon
antibodi
detect
n
protein
room
temperatur
sensit
specif
respect
relat
upe
realtim
rtpcrbase
detect
studi
camel
nasal
swab
anoth
n
protein
antigendetect
test
time
captur
enzymelink
immunosorb
assay
elisa
base
n
proteinspecif
monoclon
antibodi
mab
also
develop
shown
specif
test
seri
nasopharyng
aspir
known
posit
variou
respiratori
virus
sensit
specif
elisa
test
would
feasibl
merscov
detect
clinic
sampl
particular
pointofcar
test
dromedari
anim
may
particular
util
field
studi
ksa
elsewher
middl
east
mass
gather
context
hajj
chan
et
al
rel
afford
lower
resourceintens
would
give
advantag
rtpcr
base
method
type
context
antigendetect
test
requir
refin
yet
complet
valid
use
human
sampl
usual
sensit
naat
limit
use
date
chan
et
al
sever
serolog
assay
develop
detect
anti
merscov
antibodi
notabl
n
protein
protein
naatbas
test
gold
standard
merscov
diagnosi
serolog
assay
advantag
less
restrict
time
frame
antibodi
versu
viral
rna
detect
easier
applic
field
outbreak
situat
econom
applic
anim
test
fukushi
et
al
meyer
et
al
trivedi
et
al
howev
potenti
pitfal
serolog
test
expos
sarscov
outbreak
includ
possibl
crossreact
antigen
coronavirus
meyer
et
al
recent
assess
util
elisabas
detect
merscov
igg
compar
viral
rna
detect
carri
nasopharyng
swab
specimen
patient
hospit
riyadh
januari
decemb
merscov
outbreak
occur
alhetheel
et
al
merscov
rna
detect
patient
sampl
sampl
posit
serolog
test
includ
recent
merscov
rnaposit
merscov
rnaneg
lack
correl
naat
serolog
result
suggest
merscovigg
test
may
appropri
diagnosi
acut
infect
estim
outbreak
preval
determin
diseas
sever
alhetheel
et
al
nevertheless
serolog
test
remain
one
approv
method
merscov
case
confirm
cdc
world
health
organ
nd
center
diseas
control
prevent
one
recent
valid
studi
suggest
combin
indirect
merscov
n
elisa
combin
confirm
microneutr
assay
improv
overal
detect
sensit
specif
trivedi
et
al
anoth
recent
innov
suggest
possibl
use
competit
elisa
rather
iggigm
elisa
reli
speciesspecif
secondari
antibodi
fukushi
et
al
case
label
monoclon
antibodi
mab
merscov
protein
develop
use
compet
test
serum
antibodi
target
epitop
allow
detect
antibodi
speciesindepend
manner
fukushi
et
al
competit
elisa
success
detect
merscovspecif
antibodi
sera
infect
rat
rabbit
immun
merscov
protein
test
also
valid
sera
ethiopian
dromedari
camel
comparison
neutral
test
give
sensit
specif
respect
result
suggest
competit
elisa
might
use
serolog
test
epidemiolog
investig
ksa
elsewher
middl
east
fukushi
et
al
recommend
serolog
test
symptomat
patient
pair
sampl
collect
within
first
week
ill
second
ideal
week
later
world
health
organ
variabl
incub
period
merscov
calcul
studi
differ
countri
maill
et
al
oh
et
al
median
day
ci
day
rang
day
report
one
studi
laboratori
confirm
merscov
case
ksa
investig
franc
report
longer
incub
period
day
maill
et
al
earli
korean
outbreak
median
incub
period
mercov
found
day
oh
et
al
accommod
rang
observ
current
recommend
peopl
contact
confirm
case
must
evalu
full
day
day
contact
symptom
sign
suggest
merscov
clinic
spectrum
merscov
infect
rang
mild
respiratori
ill
sever
diseas
sever
acut
respiratori
distress
syndrom
septic
shock
multiorgan
failur
memish
et
al
b
report
case
run
sever
clinic
cours
fever
cough
predomin
symptom
symptomat
case
earli
histori
merscov
analyz
clinic
present
among
confirm
case
ksa
show
fever
temperatur
almost
patient
fever
also
found
predict
factor
progress
pneumonia
studi
follow
clinic
cours
confirm
merscov
case
korean
outbreak
progress
pneumonia
appear
slow
even
stop
fever
subsid
rhee
et
al
cough
present
infect
individu
ksa
studi
case
gastrointestin
gi
symptom
includ
abdomin
pain
vomit
diarrhea
also
report
signific
number
patient
includ
studi
gi
symptom
also
report
case
involv
south
korean
merscov
outbreak
korea
center
diseas
control
prevent
arabi
et
al
report
clinic
manifest
case
hospit
ksa
show
symptom
could
attribut
lower
respiratori
tract
arabi
et
al
upper
respiratori
tract
symptom
rhinorrhea
sore
throat
found
uncommon
arabi
et
al
renal
complic
well
known
occur
merscov
infect
first
ever
report
case
suffer
acut
kidney
injuri
zaki
et
al
proteinuria
hematuria
acut
kidney
injuri
aki
note
retrospect
studi
merscov
case
south
korea
diabet
aki
applic
continu
renal
replac
therapi
crrt
observ
risk
factor
merscovrel
mortal
cha
et
al
seizur
dic
rhabdomyolysi
also
report
complic
relat
merscov
infect
studi
seventi
patient
singl
centr
ksa
shalhoub
et
al
confirm
merscov
infect
occur
patient
comorbid
diseas
frequent
comorbid
condit
seen
patient
merscov
infect
diabet
mellitu
obes
chronic
kidney
diseas
cardiac
diseas
hypertens
well
respiratori
diseas
includ
asthma
copd
ahm
arabi
et
al
assiri
et
al
badawi
ryoo
banik
et
al
cha
et
al
korea
center
diseas
control
prevent
matsuyama
et
al
park
et
al
saad
et
al
shalhoub
et
al
diseas
sever
mortal
risk
impact
comorbid
age
exampl
one
studi
age
year
diabet
significantli
associ
mortal
patient
seri
requir
renal
replac
therapi
die
shalhoub
et
al
age
year
significantli
associ
mortal
anoth
singl
centr
studi
ksa
studi
analyz
publicli
avail
data
ksa
report
preexist
lung
diseas
appear
signific
risk
factor
sever
mortal
howev
studi
use
multivari
risk
model
ahm
banik
et
al
casecontrol
retrospect
observ
studi
ksa
korea
suggest
smoke
andor
comorbid
respiratori
diseas
signific
risk
factor
merscovrel
mortal
alraddadi
et
al
choi
et
al
korea
center
diseas
control
prevent
matsuyama
et
al
park
et
al
higher
level
mrna
protein
lung
tissu
smoker
copd
patient
compar
neversmok
may
predispos
individu
merscov
infect
sey
et
al
systemat
review
metaanalysi
shown
obes
present
merscov
case
may
influenc
diseas
sever
respiratori
condit
badawi
ryoo
asymptomat
merscov
infect
also
occur
household
contact
healthcar
worker
peopl
contact
dromedari
camel
memish
et
al
b
although
older
age
confirm
risk
factor
merscov
infect
mortal
diseas
adult
also
occur
children
albeit
rare
altawfiq
et
al
memish
et
al
thabet
et
al
pediatr
case
report
june
april
ksa
mean
age
year
commonli
infect
due
household
contact
altawfiq
et
al
mortal
lower
children
adult
commonli
associ
underli
comorbid
condit
one
studi
ksa
merscov
detect
pediatr
patient
rang
age
year
memish
et
al
asymptomat
detect
contact
investig
older
patient
symptomat
patient
underli
condit
one
die
memish
et
al
meanwhil
infant
infantil
nephrot
syndrom
treat
prednisolon
die
picu
riyadh
hospit
result
merscov
infect
clinic
cours
complic
acut
renal
failur
thabet
et
al
inform
limit
impact
merscov
pregnanc
common
sever
respiratori
viral
infect
impact
appear
sever
matern
perinat
one
studi
pregnant
women
ksa
infect
merscov
need
icu
admiss
assiri
et
al
recov
went
deliv
healthi
infant
one
mother
die
due
multipl
organ
failur
relat
infect
deliv
healthi
infant
week
gestat
anoth
die
due
complic
infect
week
infant
surgic
deliv
week
die
hour
life
one
infant
stillborn
week
assiri
et
al
one
case
second
trimest
stillbirth
merscov
outbreak
jordan
attribut
merscov
basi
matern
exposur
histori
serolog
test
payn
et
al
anoth
case
woman
week
gestat
die
due
merscovrel
complic
includ
ard
septic
shock
deliv
healthi
infant
caesarean
section
malik
et
al
studi
case
merscov
infect
ksa
leukopenia
lymphopenia
lymphocytosi
thrombocytopenia
present
case
lymphocytopenia
thrombocytopenia
also
detect
studi
includ
among
member
ksa
merscov
famili
cluster
memish
et
al
impair
liver
function
find
featur
merscov
infect
includ
studi
reveal
rais
concentr
lactat
dehydrogenas
patient
alanin
aminotransferas
patient
aspart
amino
transferas
patient
although
liver
function
test
normal
retrospect
studi
confirm
case
merscov
infect
march
may
hospit
almadinah
region
ksa
elev
liver
enzym
observ
case
sherbini
et
al
elev
urea
creatinin
level
indic
renal
impair
also
wide
observ
includ
case
seri
ksa
arabi
et
al
sherbini
et
al
anim
studi
human
express
transgen
mous
model
infect
merscov
entir
reflect
diseas
human
shown
multiorgan
damag
includ
liver
kidney
well
brain
spleen
howev
studi
transgen
mous
model
suggest
infect
merscov
result
persist
inflammatori
infiltr
lung
brain
stem
day
postinfect
respect
focal
infiltr
liver
definit
patholog
organ
recent
postmortem
histopatholog
find
male
lymphoma
patient
contract
merscov
report
alsaad
et
al
histopatholog
examin
tissu
needl
biopsi
multipl
site
includ
brain
heart
lung
liver
kidney
skelet
muscl
show
evid
viral
induc
pulmonari
extrapulmonari
patholog
chang
includ
necrotis
pneumonia
pulmonari
diffus
alveolar
damag
acut
kidney
injuri
hepat
myositi
muscl
atroph
chang
howev
notabl
find
brain
heart
first
time
ultrastructur
viral
particl
shown
renal
cell
well
pneumocyt
pulmonari
macrophag
macrophag
infiltr
skelet
muscl
alsaad
et
al
wide
rang
radiolog
featur
shown
chest
xray
merscov
infect
patient
includ
ground
glass
opacif
consolid
either
patchi
confluent
reticular
opac
nodular
opac
reticulonodular
infiltr
da
et
al
da
et
al
use
serial
chest
radiograph
use
classifi
diseas
progress
type
rang
type
initi
radiograph
deterior
follow
improv
way
type
progress
radiograph
deterior
da
et
al
importantli
studi
adult
patient
acut
merscov
infect
chest
radiograph
score
shown
independ
predictor
mortal
mean
chest
radiograph
score
significantli
higher
patient
die
surviv
pneumothorax
bilater
pleural
effus
type
radiograph
progress
significantli
higher
patient
die
da
et
al
bilater
pleural
effus
also
identifi
independ
predictor
shortterm
mortal
communityacquir
pneumonia
sar
hasley
et
al
wong
et
al
similar
radiograph
find
sensit
comput
tomographi
ct
scan
also
show
ground
glass
opac
patient
consolid
patient
togeth
patient
well
pleural
effus
interlobular
thicken
within
week
infect
da
et
al
da
et
al
diseas
progress
bronchial
abnorm
organ
pneumonia
emerg
ct
scan
da
et
al
da
et
al
mention
assum
bat
like
main
merscov
mammalian
sourc
reservoir
coronavirus
sequenc
relat
merscov
found
sampl
taken
differ
bat
speci
fig
drexler
et
al
memish
et
al
bat
coronaviru
rbd
protein
share
high
sequenc
ident
merscov
pseudotyp
virus
embed
protein
bind
human
enter
cell
vitro
protein
bind
human
low
affin
howev
introduct
mutat
bat
gene
enabl
bind
higher
affin
effici
enter
human
cell
yang
et
al
mutat
part
human
proteas
motif
junction
merscov
thu
facilit
protein
cleavag
human
cell
infect
may
instrument
transmiss
merscov
bat
human
yang
et
al
howev
posit
bat
direct
sourc
merscov
human
infect
difficult
given
infrequ
contact
human
bat
studi
ksa
found
sampl
one
bat
found
near
home
merscov
infect
patient
among
sampl
collect
differ
bat
speci
total
nucleotid
ident
merscov
sequenc
obtain
patient
memish
et
al
grow
evid
dromedari
camel
act
sourc
merscov
dromedari
camel
sera
differ
part
world
especi
middl
east
broad
area
africa
includ
nigeria
tunisia
egypt
ethiopiahav
test
posit
antimerscov
antibodi
ali
et
al
chu
et
al
farag
et
al
meyer
et
al
et
al
reusken
et
al
reusken
et
al
saqib
et
al
serolog
studi
camel
africa
middl
east
within
last
year
suggest
merscov
circul
among
camel
decad
first
document
human
be
meyer
et
al
reusken
et
al
canari
island
dromedari
camel
posit
serolog
evid
merscov
infect
origin
import
africa
year
ago
et
al
howev
lower
expect
level
merscov
human
infect
africa
suggest
may
underreport
human
case
possibl
relat
limit
resourc
test
extens
serosurvey
among
human
popul
would
help
further
understand
extent
level
merscov
infect
africa
one
studi
use
elisa
ifa
ppnt
show
evid
unrecord
case
human
merscov
kenya
similar
previou
report
ksa
liljand
et
al
et
al
genet
evid
suggest
transmiss
merscov
occur
camel
human
one
outbreak
qatar
merscov
sequenc
obtain
nasopharyng
swab
infect
human
case
resid
farm
seroposit
camel
within
farm
found
ident
anoth
case
jeddah
ksa
share
uniqu
singl
nucleotid
polymorph
snp
signatur
found
mer
cov
patient
merscovcarri
dromedari
camel
care
azhar
et
al
memish
et
al
comparison
sequenc
full
genom
merscov
variant
associ
korean
outbreak
show
similar
full
genom
cov
obtain
camel
riyadh
saudi
arabia
sabir
et
al
studi
rtpcr
test
carri
nasal
swab
sampl
camel
coronavirus
identifi
sampl
differ
lineag
coronavirus
includ
merscov
betacoronaviru
betacoronaviru
group
human
cov
alphacoronaviru
found
circul
among
dromedari
camel
sabir
et
al
studi
show
camel
age
less
year
highest
rate
infect
coronavirus
compar
older
camel
sabir
et
al
identif
camel
probabl
natur
zoonot
sourc
human
infect
merscov
econom
implic
countri
middl
east
includ
ksa
given
import
camel
trade
middl
east
africa
younan
et
al
evid
mer
cov
upon
test
anim
sheep
goat
cattl
water
buffalo
although
result
one
studi
suggest
alpaca
may
possibl
viral
reservoir
reusken
et
al
reusken
et
al
detect
merscov
new
world
camelid
rais
possibl
zoonot
spread
mer
cov
area
alpaca
farm
includ
south
america
unit
state
strong
evid
human
human
transmiss
obtain
epidemiolog
genom
studi
investig
cluster
case
hospit
among
household
contact
assiri
et
al
memish
et
al
et
al
investig
hospit
outbreak
citi
alahsa
eastern
provinc
ksa
reveal
isol
merscov
infect
patient
one
monophylet
lineag
case
occur
result
persontoperson
contact
assiri
et
al
humantohuman
transmiss
also
respons
merscov
case
report
outbreak
occur
jeddah
oboho
et
al
major
case
attribut
contact
health
care
facil
patient
highlight
role
healthcar
facil
humantohuman
transmiss
also
aros
subsequ
outbreak
includ
hospit
outbreak
riyadh
outbreak
korea
oboho
et
al
drosten
et
al
fagbo
et
al
almekhlafi
et
al
balkhi
et
al
middl
east
respiratori
syndrom
coronaviru
merscov
republ
korea
explain
healthcar
facil
humantohuman
transmiss
associ
defect
inadequ
infect
prevent
control
measur
scientif
advisori
board
ministri
health
kingdom
saudi
arabia
nd
balkhi
et
al
butt
et
al
coronaviru
infect
cotten
et
al
hast
et
al
infect
tend
milder
secondari
case
patient
infect
result
close
contact
primari
sourc
even
asymptomat
number
case
get
infect
confirm
case
low
rate
transmiss
among
household
contact
calcul
around
one
studi
done
ksa
memish
et
al
howev
epidemiolog
analysi
korean
hospit
outbreak
show
fatal
rate
significantli
differ
primari
case
subsequ
gener
kim
outbreak
highlight
danger
pose
combin
circumst
includ
primari
sourc
travel
middl
east
infect
among
secondari
tertiari
contact
due
movement
infect
individu
healthcar
facil
inadequ
infect
prevent
control
measur
nishiura
et
al
b
park
et
al
data
avail
date
merscov
fail
demonstr
potenti
result
epidem
studi
base
bayesian
analysi
carri
estim
basic
merscov
reproduct
number
repres
number
secondari
case
index
case
fulli
suscept
popul
breban
et
al
epidem
potenti
achiev
merscov
estim
howev
calcul
base
data
obtain
june
advanc
mani
import
outbreak
may
underestim
breban
et
al
case
room
complac
potenti
alway
present
viral
mutat
could
increas
zoonot
humantohuman
transmiss
thu
develop
effect
direct
therapi
remain
top
prioriti
public
health
england
phe
intern
sever
acut
respiratori
emerg
infect
consortium
isaricwho
publish
posit
paper
merscov
therapi
treatment
merscov
inform
clinician
conclud
posit
benefit
versu
risk
balanc
convalesc
plasma
lopinavirritonavir
interferon
monoclonalpolyclon
antibodi
neg
balanc
ribavirin
monotherapi
corticosteroid
treatment
merscov
inform
clinician
deem
insuffici
inform
avail
interferonribavirin
combin
therapi
nitazoxanid
chloroquin
treatment
merscov
inform
clinician
current
specif
evidencebas
therapi
vaccin
merscov
avail
recent
extens
review
candid
merscov
therapi
vaccin
rabaan
et
al
tabl
show
summari
current
propos
therapi
vaccin
includ
target
advantag
disadvantag
updat
includ
potenti
agent
emerg
sinc
public
review
alharbi
et
al
jung
et
al
langenmay
et
al
li
et
al
liu
et
al
niu
et
al
rabaan
et
al
sun
et
al
develop
target
antimerscov
therapi
avail
effect
vaccin
would
requir
coordin
effort
carri
properli
control
organ
clinic
trial
would
particular
import
ksa
given
rel
major
impact
merscov
avail
reliabl
direct
therapi
possibl
either
prophylact
vaccin
programm
vaccin
could
rapidli
avail
event
major
outbreak
would
major
advantag
effect
tackl
diseas
protein
bind
target
mani
propos
direct
merscov
therapi
includ
larg
number
antibodi
target
interact
either
viral
host
side
corti
et
al
du
et
al
houser
et
al
jiang
et
al
johnson
et
al
li
et
al
niu
et
al
ohnuma
et
al
qiu
et
al
ying
et
al
yu
et
al
monoclon
antibodi
rbd
region
particularli
strong
neutral
capac
although
fulllength
target
antibodi
may
greater
potenti
vaccin
context
given
larger
number
target
epitop
reduc
chanc
escap
mutat
corti
et
al
du
et
al
houser
et
al
jiang
et
al
johnson
et
al
li
et
al
niu
et
al
ohnuma
et
al
qiu
et
al
ying
et
al
yu
et
al
fusion
product
truncat
rbd
residu
join
fc
portion
human
igg
could
bind
human
inhibit
merscov
infect
vitro
cell
cultur
vivo
infect
mice
tabl
du
et
al
vivo
studi
mice
also
indic
intranas
administr
fusion
product
induc
compar
sustain
igg
humor
respons
subcutan
inject
superior
cellular
immun
respons
local
mucos
respons
lung
zhang
et
al
use
adjuv
particularli
addavax
significantli
improv
humor
cell
respons
subcutan
immun
mice
zhang
et
al
recent
highyield
cho
cell
line
capabl
largescal
product
rbdfc
fusion
product
describ
strengthen
possibl
sustain
manufactur
human
test
potenti
vaccin
antigen
nyon
et
al
anoth
recent
studi
show
recombin
rbd
incorpor
mutat
aros
differ
merscov
outbreak
camel
strain
could
induc
neutral
antibodi
respons
sever
merscov
pseudovirus
tai
et
al
particularli
promis
antibodi
candid
merscov
therapi
human
antibodi
target
ntermin
domain
ntd
rbd
tabl
corti
et
al
isol
b
cell
merscovinfect
human
donor
use
establish
stabl
cho
cell
line
clinic
grade
antibodi
reliabl
avail
corti
et
al
type
readi
avail
would
particular
benefit
ksa
outbreak
situat
prophylact
therapeut
activ
merscov
infect
transgen
mous
model
type
interferon
receptor
ifnar
ko
corti
et
al
anoth
human
antirbd
antibodi
shown
promis
result
nonhuman
primat
model
ie
rhesu
monkey
infect
merscov
prophylact
reduc
lung
patholog
johnson
et
al
recent
suit
potent
merscovneutr
anti
protein
antibodi
deriv
b
cell
infect
patient
specif
first
import
case
china
niu
et
al
two
antibodi
particular
potent
synergist
neutral
vitro
activ
pseudotyp
live
merscov
tabl
niu
et
al
antibodi
target
differ
epitop
vitro
antibodi
human
rbd
vitro
vivo
mous
houser
et
al
ying
et
al
antibodi
human
rbd
vitro
yu
et
al
antibodi
mousehuman
rbd
vitro
vivo
mous
prophylact
therapeut
antibodi
mousehuman
rbd
du
et
al
et
al
nyon
et
al
tai
et
al
zhang
et
al
zhang
et
al
cell
neutral
antibodi
respons
enter
human
clinic
trial
potenti
veterinari
use
langenmay
et
al
volz
et
al
adenoviru
express
fulllength
vivo
mous
cell
neutral
antibodi
respons
measl
viru
express
fulllength
vivo
mous
cell
neutral
antibodi
respons
chimer
vesicular
stomat
viru
vsv
express
fulllength
vivo
rhesu
monkey
cell
neutral
antibodi
respons
liu
et
al
chimpanze
adenoviru
express
fulllength
vivo
mous
cell
neutral
antibodi
respons
enter
human
clinic
trial
potenti
veterinari
use
alharbi
et
al
plasmid
vaccin
vitro
vivo
mous
camel
macaqu
human
clinic
trial
cell
neutral
antibodi
respons
phase
clinic
trial
inovio
muthumani
et
al
viral
membran
fusion
viral
peptid
vitro
lu
et
al
viral
peptid
vitro
vivo
mous
block
bundl
format
enhanc
effect
potenti
intranas
treatment
bosch
et
al
channappanavar
et
al
liu
et
al
three
two
protein
vitro
inhibit
fusion
entri
sun
et
al
continu
next
page
epitop
almost
entir
overlap
receptor
bind
site
niu
et
al
thu
wide
rang
protein
direct
antibodi
fusion
product
avail
potenti
passiv
immun
strategi
thu
far
enter
human
clinic
trial
avail
monoclon
antibodi
may
particular
use
outbreak
situat
continu
aris
ksa
potenti
proteintarget
vaccin
candid
includ
nanoparticl
express
fulllength
protein
activ
immun
strategi
use
vector
includ
modifi
vaccinia
adenovirus
measl
virus
plasmid
express
fulllength
protein
potenti
vaccin
candid
discuss
detail
next
section
alharbi
et
al
guo
et
al
inovio
jung
et
al
langenmay
et
al
liu
et
al
malczyk
et
al
muthumani
et
al
volz
et
al
antivir
peptid
target
region
protein
henc
virushost
cell
fusion
also
shown
potenti
therapeut
activ
cell
cultur
transgen
anim
studi
bosch
et
al
channappanavar
et
al
liu
et
al
liu
et
al
peptid
cover
residu
reduc
viral
replic
fusion
vitro
lu
et
al
analogu
block
fusion
even
potent
vitro
inhibit
pseudoviru
infect
block
bundl
format
bosch
et
al
channappanavar
et
al
liu
et
al
conveni
intranas
administr
vivo
transgen
mice
protect
merscov
infect
enhanc
coadministr
bosch
et
al
recent
synthet
protein
name
bundl
deriv
bundl
involv
merscov
fusion
shown
bind
strongli
effect
inhibit
pseudotyp
merscov
fusion
entri
vitro
studi
tabl
sun
et
al
repres
anoth
potenti
use
direct
merscov
therapeut
candid
present
combin
antivir
therapi
tend
use
patient
develop
respiratori
ill
base
experi
sarscov
therapi
exampl
pegyl
interferon
ifn
ribavirin
andor
lopinavirritonavir
altawfiq
et
al
de
wild
et
al
khalid
et
al
khalid
et
al
kim
et
al
lau
et
al
omrani
et
al
shalhoub
et
al
spanaki
et
al
strayer
et
al
vitro
anim
studi
suggest
potenti
efficaci
vivo
clinic
evid
less
wellestablish
altawfiq
et
al
chan
et
al
de
wild
et
al
falzarano
et
al
b
khalid
et
al
khalid
et
al
kim
et
al
lau
et
al
omrani
et
al
shalhoub
et
al
spanaki
et
al
strayer
et
al
zheng
wang
clinic
studi
mainli
confin
case
studi
case
seri
retrospect
analys
altawfiq
et
al
de
wild
et
al
khalid
et
al
khalid
et
al
kim
et
al
lau
et
al
omrani
et
al
spanaki
et
al
strayer
et
al
thu
need
properli
control
clinic
trial
ifn
combin
therapi
merscov
prefer
earli
ill
seem
effect
type
therapi
function
essenti
challeng
immun
evas
tactic
employ
viru
altawfiq
et
al
chan
et
al
de
wild
et
al
falzarano
et
al
b
khalid
et
al
khalid
et
al
kim
et
al
lau
et
al
omrani
et
al
shalhoub
et
al
spanaki
et
al
strayer
et
al
zheng
wang
recent
result
studi
use
vitro
human
ex
vivo
explant
cultur
suggest
combin
cyclosporin
synergist
effect
reduct
merscov
replic
base
falzarano
et
al
b
zheng
wang
lopinavir
chan
et
al
de
wild
et
al
rambaut
immunomodul
induct
ifnstimul
gene
express
suggest
clinic
trial
may
warrant
tabl
li
et
al
corticosteroid
treatment
also
commonli
use
treatment
critic
ill
merscov
patient
despit
find
isaricwho
group
risk
may
outweigh
benefit
treatment
merscov
inform
clinician
recent
margin
structur
model
studi
carri
data
critic
ill
icu
patient
merscov
receiv
corticosteroid
ksa
health
facil
septemb
octob
arabi
et
al
result
indic
corticosteroid
therapi
associ
significantli
differ
mortal
outcom
timevari
confound
effect
worsen
condit
patient
consid
associ
delay
clearanc
viral
rna
find
suggest
bia
determin
potenti
harm
effect
therapi
emerg
observ
studi
baselin
characterist
rather
timevari
characterist
patient
consid
highlight
need
properli
control
clinic
trial
data
anoth
use
tactic
would
make
use
therapi
alreadi
clinic
approv
purpos
sound
scientif
rational
possibl
use
merscov
therapi
exampl
would
camostat
inhibitor
shirato
et
al
zhou
et
al
camostat
shown
block
infect
viral
spread
pathogenesi
pathogen
mous
model
sarscov
would
like
similar
inhibitori
effect
merscov
zhou
et
al
camostat
alreadi
use
clinic
treatment
chronic
pancreat
thu
potenti
safe
effect
therapeut
option
anoth
inhibitor
nafamostat
also
identifi
vitro
potent
inhibitor
merscov
proteinmedi
hostvir
membran
fusion
also
alreadi
clinic
use
fdaapprov
anticoagul
yamamoto
et
al
screen
fdaapprov
drug
inhibitor
cathepsin
l
call
teicoplanin
shown
block
cytoplasm
entri
merscov
sarscov
ebola
pseudovirus
qian
et
al
zhou
et
al
teicoplanin
current
clinic
use
antibiot
seriou
gramposit
bacteri
infect
deriv
includ
dalbavancin
oritavancin
telavancin
also
block
cytoplasm
viral
entri
therapi
target
host
proteas
anoth
possibl
target
viral
proteas
encod
pl
pro
activ
mediat
initi
process
fig
forni
et
al
hagemeij
et
al
neuman
et
al
inhibit
vitro
sarscov
pl
pro
inhibitor
commerci
compound
life
chemic
cheng
et
al
clasman
et
al
main
merscov
proteas
encod
fig
target
vitro
vivo
lopinavir
proteas
inhibitor
activ
sarscov
mpro
emerg
screen
librari
fdaapprov
drug
one
compound
inhibit
merscov
viral
activ
low
micromolar
rang
de
wild
et
al
rambaut
howev
lopinavir
clinic
efficaci
convincingli
establish
merscov
treatment
gener
use
clinic
combin
ifn
data
avail
case
studi
seri
marmoset
infect
merscov
gave
favor
clinic
outcom
reduc
mortal
combin
ritonavir
earli
treatment
within
day
symptom
onset
convalesc
plasma
hyperimmun
iv
immunoglobulin
hvig
plasma
convalesc
donor
associ
decreas
viral
load
reduc
mortal
influenza
sarscov
infect
although
qualiti
studi
sarscov
uneven
adequ
clinic
trial
hui
lee
hung
et
al
mairjenkin
et
al
stockman
et
al
phe
isaricwho
posit
paper
identifi
convalesc
plasma
potenti
treatment
merscov
infect
howev
clinic
trial
yet
complet
treatment
merscov
inform
clinician
clinic
trial
ksa
safeti
efficaci
convalesc
plasma
treatment
critic
ill
merscov
patient
initi
may
still
list
activ
recruit
clinicaltrialsgov
identifi
due
report
june
common
mani
convalesc
plasma
trial
affect
logist
technic
issu
avail
suffici
donor
suffici
level
merscov
antibodi
plasma
collect
arabi
et
al
modjarrad
clinic
data
spars
use
convalesc
plasma
treatment
merscov
confin
case
report
role
patient
recoveri
unclear
arabi
et
al
kapoor
et
al
use
marmoset
infect
merscov
recent
studi
indic
convalesc
plasma
treatment
reduc
sign
clinic
diseas
includ
reduc
respiratori
tract
viral
load
induc
decreas
gross
patholog
van
doremalen
et
al
thu
convalesc
plasma
possibl
candid
merscov
therapi
technic
logist
difficulti
collect
prepar
uncertainti
extent
protect
effect
may
undermin
potenti
use
studi
ksa
suggest
patient
surviv
merscov
produc
antimerscov
igg
neutral
antibodi
antibodi
level
weakli
invers
correl
lower
respiratori
tract
lrt
viral
load
would
insuffici
elimin
lrt
viru
cell
respons
merscov
infect
yet
wellunderstood
recent
studi
survivor
merscov
ksa
cell
respons
develop
merscov
specif
neutral
antibodi
respons
along
memori
cell
cell
respons
shown
correl
diseas
sever
virusspecif
cell
respons
observ
merscov
survivor
even
serolog
respons
observ
robust
cell
respons
might
therefor
import
earli
clearanc
viral
infect
henc
antibodi
cell
respons
may
develop
strongli
measur
cell
respons
along
antibodi
may
also
give
accur
estim
diseas
preval
vitro
studi
shown
merscov
infect
downregul
mhc
antigen
present
molecul
via
methylationbas
mechan
could
implic
cell
humor
adapt
immun
respons
old
ref
menacheri
et
al
combin
appar
inadequaci
humor
adapt
immun
respons
clear
merscov
high
mortal
rate
associ
diseas
point
import
vaccin
develop
particularli
middl
east
ksa
particular
induct
antibodi
cell
respons
would
import
featur
use
vaccin
issu
guidelin
propos
merscov
vaccin
consid
prospect
vaccin
casebycas
basi
target
product
profil
merscov
vaccin
distinguish
vaccin
type
aim
differ
defin
target
popul
direct
relev
middl
east
type
dromedari
camel
vaccin
design
prevent
camelcamel
camelhuman
transmiss
prophylact
human
vaccin
individu
may
longterm
risk
exampl
healthcar
worker
peopl
work
potenti
infect
anim
final
human
vaccin
would
suitabl
use
outbreak
target
product
profil
merscov
vaccin
defin
prefer
minim
accept
criteria
vaccin
type
guidelin
particularli
welcom
context
difficulti
prevail
defin
popul
target
merscov
vaccin
program
random
clinic
trial
especi
given
current
rel
low
incid
diseas
human
difficulti
develop
suitabl
small
anim
model
depend
transduc
transgen
human
mous
model
cho
et
al
therapi
develop
protein
focu
mani
candid
vaccin
alharbi
et
al
coleman
et
al
guo
et
al
inovio
jung
et
al
langenmay
et
al
liu
et
al
malczyk
et
al
muthumani
et
al
volz
et
al
vector
includ
modifi
vaccinia
viru
ankara
mva
adenovirus
measl
viru
chimer
vesicular
stomat
viru
vsv
chimpanze
adenoviru
success
use
express
merscov
protein
induc
neutral
antibodi
mice
anim
model
includ
camel
rhesu
monkey
tabl
alharbi
et
al
coleman
et
al
guo
et
al
inovio
jung
et
al
langenmay
et
al
liu
et
al
malczyk
et
al
muthumani
et
al
volz
et
al
viru
vector
advantag
good
safeti
profil
human
product
candid
vaccin
potenti
veterinari
use
dromedari
camel
order
reduc
crossspeci
transmiss
welcom
develop
keep
guidelin
includ
proteinexpress
mvabas
vaccin
mvamerss
strong
neutral
antibodi
cytotox
lymphocyt
respons
reduct
viral
replic
transduc
mice
induc
mucos
immun
merscovinfect
dromedari
camel
langenmay
et
al
volz
et
al
virus
due
enter
human
clinic
trial
soon
candid
prophylact
merscov
vaccin
anoth
potenti
vaccin
due
evalu
camel
enter
human
clinic
trial
mer
vaccin
tabl
alharbi
et
al
mous
studi
singl
dose
mer
leader
sequenc
human
tissu
plasminogen
activ
gene
tpa
induc
equival
humor
respons
dose
mvabas
vaccin
alharbi
et
al
anoth
potenti
effici
prophylact
vaccin
strategi
recent
test
mice
involv
heterolog
primeboost
vaccin
regimen
use
combin
protein
nanoparticl
heterolog
primeboost
elicit
antimerscov
neutral
antibodi
simultan
respons
homolog
primeboost
regimen
induc
simultan
respons
homolog
also
induc
neutral
antibodi
respons
immun
schedul
involv
induc
cell
activ
includ
protein
nanoparticl
thu
overal
heterolog
primeboost
schedul
gave
superior
result
like
induc
effect
sustain
immun
respons
merscov
type
vaccin
would
keep
guidelin
dnaplasmidbas
vaccin
call
encod
merscov
protein
codevelop
inovio
geneon
life
scienc
inc
walter
reed
armi
institut
research
meanwhil
first
potenti
merscov
vaccin
test
clinic
trial
human
inovio
phase
clinic
trial
healthi
volunt
ongo
evalu
safeti
abil
gener
sustain
humor
cellular
immun
respons
year
period
inovio
preclin
trial
perform
mice
camel
macaqu
vaccin
induc
robust
immun
respons
effect
prevent
viral
infect
muthumani
et
al
sinc
initi
descript
merscov
exact
high
mortal
rate
particularli
ksa
epidem
potenti
evid
thu
far
potenti
exist
viral
mutat
could
increas
zoonot
andor
humantohuman
transmiss
outbreak
tend
occur
healthcar
facil
set
infect
rate
ksa
reduc
stringent
effort
improv
infect
control
prevent
standard
howev
inclus
merscov
list
prioriti
blueprint
diseas
time
remind
urgent
need
acceler
research
develop
diseas
potenti
caus
public
health
emerg
current
directli
efficaci
drug
andor
vaccin
avail
list
blueprint
prioriti
diseas
viru
clinic
spectrum
vari
asymptomat
mildmoder
diseas
potenti
sever
diseas
high
case
fatal
rate
impact
asymptomat
case
includ
healthcar
worker
transmiss
yet
fulli
understood
multipl
studi
suggest
dromedari
camel
like
main
zoonot
sourc
merscov
infect
human
major
implic
valuabl
camel
trade
middl
east
africa
appar
lower
expect
number
human
case
africa
may
attribut
inadequaci
surveil
system
address
role
anim
bat
hedgehog
also
need
clarif
possibl
emerg
alpaca
potenti
zoonot
sourc
deserv
attent
naat
detect
system
highli
sensit
specif
attent
need
effect
feasibl
detect
system
employ
field
major
ongo
issu
lack
accept
specif
treatment
merscov
infect
current
treatment
guidelin
much
base
experi
sarscov
therapi
despit
numer
key
differ
coronavirus
urgent
need
move
vitro
vivo
model
clinic
case
studi
properli
manag
random
control
trial
numer
direct
therapeut
vaccin
candid
identifi
clarif
issu
durat
isol
patient
merscov
infect
also
need
thu
view
prioriti
includ
clarif
transmiss
mode
exampl
role
asymptomat
individu
diseas
spread
ongo
vigil
monitor
possibl
crossspeci
transmiss
ongo
need
wellvalid
human
anim
sera
panel
need
add
urgenc
clinic
respons
progress
includ
advanc
possibl
direct
therapi
human
clinic
trial
progress
undoubtedli
made
understand
merscov
much
remain
done
reduc
impact
diseas
particularli
ksa
ensur
futur
outbreak
effect
contain
manuscript
review
articl
involv
research
protocol
requir
approv
relev
institut
review
board
ethic
committe
special
thank
research
center
dr
sulaiman
alhabib
medic
group
support
research
project
